Journal
ACTA PHARMACOLOGICA SINICA
Volume 31, Issue 9, Pages 1172-1180Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/aps.2010.103
Keywords
poly(ADP-ribose) polymerase inhibitor; DNA repair; BRCA1/2; anticancer agents; homologous recombination
Funding
- National Natural Science Foundation of China (NSFC) [30772588, 30721005]
- National Science & Technology of China [2009ZX09301-001]
- Science and Technology Commission of Shanghai Municipality (STCSM) [08DZ1980200]
Ask authors/readers for more resources
The year of 2005 was a watershed in the history of poly(ADP-ribose) polymerase (PARP) inhibitors due to the important findings of selective killing in BRCA-deficient cancers by PARP inhibition. The findings made PARP inhibition one of the most promising new therapeutic approaches to cancers, especially to those with specific defects. With AZD2281 and BSI-201 entering phase III clinical trials, the final application of PARP inhibitors in clinic would come true soon. This current paper will review the major advances in targeting PARP for cancer therapy and discuss the existing questions, the answers to which may influence the future of PARP inhibitors as cancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available